SCHEMBL29630576

SCHEMBL29630576

NCC(=O)NCC(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)NCC(=O)O

nearest known ligand 0.55

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
▸ OPRD1 P41143 7/20 0.55
▸ OPRM1 P35372 5/20 0.55
▸ OPRK1 P41145 1/20 0.55
▸ CHRND Q07001 7/20 0.52
▸ CHRNA1 P02708 3/20 0.52
▸ CHRNG P07510 3/20 0.52
▸ CHRNB1 P11230 3/20 0.52
▸ GRIA1 P42261 3/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3952781 0.94 CHRND (0.55) OPRD1OPRM1OPRK1CHRNDCHRNA1
SCHEMBL7586744 0.94 CHRND (0.55) OPRD1OPRM1OPRK1CHRNDCHRNA1
SCHEMBL29590774 0.92 OPRD1 (0.51) OPRD1OPRM1OPRK1CHRNDCHRNA1
SCHEMBL7211697 0.90 OPRD1 (0.52) OPRD1OPRM1OPRK1CHRNDCHRNA1
SCHEMBL6828134 0.90 OPRD1 (0.52) OPRD1OPRM1OPRK1CHRNDCHRNA1
SCHEMBL7042469 0.90 OPRD1 (0.52) OPRD1OPRM1OPRK1CHRNDCHRNA1
SCHEMBL30637588 0.89 OPRD1 (0.61) OPRD1OPRM1OPRK1CHRNDCHRNA1
SCHEMBL29794253 0.89 OPRD1 (0.61) OPRD1OPRM1OPRK1CHRNDCHRNA1
SCHEMBL30637600 0.89 OPRD1 (0.61) OPRD1OPRM1OPRK1CHRNDCHRNA1
SCHEMBL30939437 0.89 OPRD1 (0.51) OPRD1OPRM1OPRK1CHRNDCHRNA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025120085-A1 MODULAR LINKER COMPOUND FOR TARGET-BINDING DRUG CONJUGATES HEIDELBERG PHARMA RESEARCH GMBH (DE) 2025-06-12 — — WO claimed
US-20250186606-A1 MODULAR LINKER COMPOUND FOR TARGET-BINDING DRUG CONJUGATES HEIDELBERG PHARMA RESEARCH GMBH (DE) 2025-06-12 — — US claimed
US-20250186606-A1 MODULAR LINKER COMPOUND FOR TARGET-BINDING DRUG CONJUGATES HEIDELBERG PHARMA RESEARCH GMBH (DE) 2025-06-12 — — US disclosed
WO-2025120085-A1 MODULAR LINKER COMPOUND FOR TARGET-BINDING DRUG CONJUGATES HEIDELBERG PHARMA RESEARCH GMBH (DE) 2025-06-12 — — WO disclosed
US-11807899-B2 Biochemical reaction methods and reagents comprising intrinsically disordered regions Biocrucible Limited 2023-11-07 — — US disclosed
US-20220145378-A1 BIOCHEMICAL REACTION METHODS AND REAGENTS COMPRISING INTRINSICALLY DISORDERED REGIONS Biocrucible Limited (GB) 2022-05-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250186606-A1 MODULAR LINKER COMPOUND FOR TARGET-BINDING DRUG CONJUGATES BCR, TBCD, TBC1D5 OPRD1 4114/4885OPRM1 3331/4885OPRK1 4480/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback